That big R&D PARP win Clovis CEO Mahaffy touted a few weeks ago? The FDA isn't buying it
Once again, you’ll have to go to the fine print in an SEC filing to find the bad news that has been steadily killing Clovis Oncology’s share price for years.
Just weeks after Clovis did its level best to trumpet a big win for its stunted cash calf Rubraca in a Phase III ovarian cancer study, you can go to the SEC site to see why its bruised and battered stock price is getting pummeled one more time.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.